Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873418 | PMC |
| http://dx.doi.org/10.1136/gutjnl-2020-322038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enteric nervous system dysfunction as a driver of central nervous system disorders: The Forgotten brain in neurological disease.
Neuroscience
March 2025
Neuroscience Initiative, Advanced Science Research Center, The City University of New York (CUNY) Graduate Center, New York, NY 10031, USA.
The Enteric Nervous System (ENS), often called the "second brain," is a complex network of neurons and glial cells within the gastrointestinal (GI) tract. It functions autonomously while maintaining close communication with the central nervous system (CNS) via the gut-brain axis (GBA). ENS dysfunction plays a crucial role in neurodegenerative and neurodevelopmental disorders, including Parkinson's disease, Alzheimer's disease, and autism spectrum disorder.
View Article and Find Full Text PDFGut microbiota therapy in gastrointestinal diseases.
Front Cell Dev Biol
February 2025
Medicine and Engineering Interdisciplinary Research Laboratory of Nursing & Materials, Nursing Key Laboratory of Sichuan Province, West China Hospital, West China School of Nursing, Sichuan University, Chengdu, Sichuan, China.
The human gut microbiota, consisting of trillions of microorganisms, plays a crucial role in gastrointestinal (GI) health and disease. Dysbiosis, an imbalance in microbial composition, has been linked to a range of GI disorders, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, and colorectal cancer. These conditions are influenced by the interactions between the gut microbiota, the host immune system, and the gut-brain axis.
View Article and Find Full Text PDFAdvances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.
Adv Sci (Weinh)
February 2025
Department of Orthopedics, The Fourth Affiliated Hospital of China Medical University, China Medical University, Liao Ning, Shen Yang, 110032, P. R. China.
This article provides an overview of the advancements in the application of fecal microbiota transplantation (FMT) in treating diseases related to intestinal dysbiosis. FMT involves the transfer of healthy donor fecal microbiota into the patient's body, aiming to restore the balance of intestinal microbiota and thereby treat a variety of intestinal diseases such as recurrent Clostridioides difficile infection (rCDI), inflammatory bowel disease (IBD), constipation, short bowel syndrome (SBS), and irritable bowel syndrome (IBS). While FMT has shown high efficacy in the treatment of rCDI, further research is needed for its application in other chronic conditions.
View Article and Find Full Text PDFPlacebo response variability on health-related quality of life outcomes in irritable bowel syndrome: an arm-based network meta-analysis.
Qual Life Res
February 2025
Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine，No.1166 Liutai Avenue, Wenjiang District, Chengdu, China.
Objectives: The impact of placebo response on health outcomes in various diseases, including IBS, is significant. To better understand the effect of different placebo administration methods on the observed outcomes in IBS studies, this meta-analysis aims to explore research findings on the degree of improvement.
Methods: The meta-analysis included 45 randomized, double-blind, placebo-controlled clinical trials involving 5174 patients with confirmed IBS (excluding those with significant comorbidities).
Irritable bowel syndrome, the gut microbiome, and diet.
Curr Opin Endocrinol Diabetes Obes
February 2025
Purpose Of Review: To provide an update of recent studies exploring the role of the gut microbiota and diet in the pathogenesis and treatment of irritable bowel syndrome (IBS).
Recent Findings: The human gut microbiome has been recognized as an important, active source of signaling molecules that explain in part the disorder of the gut brain interaction (DGBI) in IBS. Subsequent changes in the metabolome such as the production of short-chain fatty acids (SCFA) and serotonin are associated with IBS symptoms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!